Lataz-Co (Timolol Maleate, Latanoprost)

• Lataz-Co combines a beta‑blocker and a prostaglandin analog to manage intra‑ocular pressure in glaucoma and related conditions.
• Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic nerve damage.
• Ocular hypertension: reduces elevated eye pressure to lower the risk of developing glaucoma.
• Post‑surgical pressure control: assists in maintaining target pressure after glaucoma surgery.

• Timolol maleate acts as a non‑selective beta‑adrenergic antagonist, decreasing aqueous humor production by the ciliary body. Latanoprost, a prostaglandin F2α analog, enhances uveoscleral outflow of aqueous humor. The combined effect results in a net reduction of intra‑ocular pressure, helping to protect the optic nerve in glaucoma patients.

Lataz-Co may cause a range of ocular and systemic reactions.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision
• Redness of the eye
• Itching or mild allergic reaction
• Dry eye or foreign‑body sensation
• Temporary changes in eyelash growth

Serious or Rare Side Effects

• Severe allergic reaction (e.g., swelling, rash, difficulty breathing)
• Exacerbation of asthma or chronic obstructive pulmonary disease
• Marked bradycardia or hypotension
• Uveitis or intra‑ocular inflammation
• Corneal edema or keratitis
• Persistent visual disturbances

• Before using Lataz-Co, consider the following safety measures.
• Assess cardiovascular status: avoid in patients with severe bradycardia or heart block.
• Monitor respiratory conditions: use cautiously in individuals with asthma or COPD.
• Check ocular surface health: may worsen dry eye or existing corneal disease.
• Avoid concurrent miotics: combined use can increase risk of ocular side effects.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature below 25°C: keep in original pack, protect from light and moisture.

Lataz-Co can interact with several systemic and ocular medications.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers (e.g., propranolol): additive cardiovascular depression.
• Other prostaglandin analog eye drops: increased risk of ocular irritation.
• Topical adrenergic agonists (e.g., epinephrine): may diminish IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitors (e.g., dorzolamide): additive intra‑ocular pressure reduction.

• Topical anesthetics: heightened corneal toxicity risk.
• Systemic antihypertensives: possible additive hypotensive effect.